Key result
Complete revascularization is linked to improved 3-year outcomes over incomplete revascularization in multivessel NSTEMI.
Why the study?
The optimal revascularization strategy for NSTEMI patients with multivessel disease remains controversial.
Does complete revascularization improve clinical outcomes compared to incomplete revascularization in NSTEMI patients with multivessel disease?
Cohort (n=6,987)
Yes
Does complete revascularization improve clinical outcomes compared to incomplete revascularization in NSTEMI patients with multivessel disease?
Answers are grounded in this paper and cite their sources.
In NSTEMI patients with multivessel disease, complete revascularization is associated with a significantly lower 3-year risk of major adverse cardiac events compared to incomplete revascularization.
BACKGROUND: The optimal revascularization strategy for patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remains controversial. OBJECTIVES: This study aimed to compare the 3-year clinical outcomes of incomplete revascularization (IR) vs complete revascularization (CR) in NSTEMI patients with multivessel disease. METHODS: Among 29,625 patients enrolled in the nationwide pooled registry of the KAMIR-NIH (Korea Acute Myocardial Infarction Registry-National Institutes of Health) and KAMIR-V, 6,987 NSTEMI patients with multivessel disease who underwent percutaneous coronary intervention were analyzed. CR was defined as residual stenosis <30% in all vessels ≥2.25 mm with TIMI flow grade 3. The primary endpoint was major adverse cardiac events at 3 years, a composite of all-cause death, recurrent myocardial infarction, unplanned repeat revascularization, and hospitalization for heart failure. RESULTS: Of 6,987 patients, 3,072 underwent CR and 3,915 IR. The majority of patients underwent percutaneous coronary intervention for non-infarct-related artery during index procedure (6,144 of 6,987; 88.0%). CR was associated with a lower 3-year risk of major adverse cardiac events compared with IR (18.6% vs 26.9%; adjusted HR: 0.75; 95% CI: 0.66-0.85; P < 0.001), driven by reductions in cardiac death or recurrent myocardial infarction (6.9% vs 10.4%; adjusted HR: 0.76; 95% CI: 0.60-0.95; P = 0.015) and unplanned repeat revascularization (8.6% vs 13.1%; adjusted HR: 0.68; 95% CI: 0.56-0.82; P < 0.001). Findings were consistent after adjustment using propensity score matching and inverse probability weighting. CONCLUSIONS: In NSTEMI patients with multivessel disease, CR was associated with significantly improved 3-year clinical outcomes compared with IR.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted a cohort in NSTEMI with multivessel disease (n=6,987). Complete revascularization vs. Incomplete revascularization was evaluated on major adverse cardiac events at 3 years, a composite of all-cause death, recurrent myocardial infarction, unplanned repeat revascularization, and hospitalization for heart failure (HR 0.75, 95% CI 0.66-0.85, p=< 0.001). Complete revascularization was associated with a lower 3-year risk of major adverse cardiac events compared with incomplete revascularization.
Synapse has enriched 10 related papers. Consider them for comparative context: